Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Xarelto Lawsuits Move Forward As FDA Approves Label Changes For Prescription Blood Thinner, The Oliver Law Group Comments
  • USA - English


News provided by

The Oliver Law Group

Jan 28, 2015, 14:25 ET

Share this article

Share toX

Share this article

Share toX

To learn more about filing a Xarelto lawsuit, please contact our office by calling 800-939-7878 today or visit www.legalactionnow.com.
To learn more about filing a Xarelto lawsuit, please contact our office by calling 800-939-7878 today or visit www.legalactionnow.com.

To learn more about filing a Xarelto lawsuit, please contact our office by calling 800-939-7878 today or visit www.legalactionnow.com.

Post this

Detroit, MI (PRWEB) January 28, 2015 -- Xarelto Lawsuits News & Information: The Oliver Law Group reports that as litigation is underway for Xarelto lawsuits alleging anticoagulant medication can lead to serious or fatal bleeding, the U.S. Food and Drug Administration (FDA) has approved revisions to the drug safety label of Xarelto tablets. The term, “thrombocytopenia,” a blood and lymphatic system disorder, is now included under the “ Adverse Reaction” section on the label. The firm notes, that also under Adverse Reaction, the term “cytolytic hepatitis” was replaced with “hepatitis (including hepatocellular injury).” Pfizer Inc., which manufactures the Xarelto blood thinner, explained in the prescribing information that because there is an uncertain size of the population voluntarily reporting these adverse reactions, it is not always possible to estimate how frequently these adverse actions occur or establish whether the reactions were caused by exposure to the drug.
[fda.gov/Safety/MedWatch/SafetyInformation/ucm367392.htm, December 2014]
[accessdata.fda.gov/drugsatfda_docs/label/2014/022406s015lbl.pdf, December 2014]

"We are working with men and women from around the country who believe they have suffered side-effects from the Xarelto blood thinner and welcome any label changes warning of prescription drug side-effects the FDA approves," states The Oliver Law Group.

Xarelto (rivaroxaban) is an oral anticoagulant approved by the FDA to treat blood clots in the leg (deep vein thrombosis) and lungs (pulmonary embolism) and to reduce the risk of stroke and blood clots in patients with atrial fibrillation (irregular heart rhythms). Xarelto has been considered a new generation blood thinner compared to warfarin (Coumadin, Jantoven), which has been on the market for 60 years. According to Xarelto's drug safety information, the most common adverse reaction to the anticoagulant is bleeding. The FDA notes that newer blood thinners like Xarelto, Eliquis and Pradaxa do not have antidotes to stop severe bleeding, whereas the 60-year-old warfarin uses vitamin K as an antidote should severe bleeding occur in patients who take the medication.
[fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm, November 2, 2012]
[fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]

The firm recently found a study published in the November 2014 issue of Annals of Internal Medicine that found people who use anticoagulants such as Xarelto to treat atrial fibrillation and take nonsteroidal anti-inflammatory drugs (NSAID), such as aspirin, Motrin and Advil to relieve pain, are at an increased risk for serious bleeding. The study, conducted by researchers in Denmark, used data from 150,900 Danish patients who were hospitalized with atrial fibrillation between 1997 and 2011. The study found that after three months of taking an anticoagulant and being prescribed 14 days of NSAID medication, there were 3.5 serious bleeding events per 1,000 patients compared with 1.5 serious bleeding events per 1,000 patients who were not taking NSAIDs along with anticoagulants. Researchers noted that NSAID and anticoagulant use were associated with increased risks of serious bleeding no matter what type of blood thinner or pain-killer were prescribed. [annals.org/article.aspx?articleid=1935053, November 18, 2014]

The firm also notes, that court documents indicate that Germany-based Bayer AG, which makes Xarelto, and Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals, Inc. face lawsuits over the blood thinner medication. In December, the U.S. Judicial Panel on Multidistrict Litigation transferred all federally filed Xarelto lawsuits to the U.S. District Court, Eastern District of Louisiana for coordinated pretrial proceedings. One of the lawsuits recently filed was a wrongful death complaint filed on behalf of a patient who allegedly suffered fatal bleeding as a result of using Xarelto. According to the Xarelto complaint, the woman was prescribed the blood thinner in 2012, and nearly four months later, the woman was hospitalized for gastrointestinal and rectal bleeding. According to the complaint, physicians could not reverse the blood thinner's effects and the woman died three days later. The case was filed November 19, 2014 in the U.S. District Court, Middle District of Florida. (8:14-cv-02901)

The Oliver Law Group P.C. is speaking with clients across the country and offers free Xarelto lawsuit reviews to individuals who believe they have suffered serious internal bleeding and other complications due to their use of the blood thinner. To learn more about Xarelto side-effects and the ongoing Xarelto lawsuits, please contact our office by calling 800-939-7878 today.

About The Oliver Law Group P.C. And Filing A Xarelto Lawsuit

The Oliver Law Group P.C. is a different kind of law firm. One that focuses on the needs of the injured first. A compassionate law firm dedicated to fighting for the rights of victims and their families, and doing everything necessary to ensure those rights.

The experience of a large firm. The 1-on-1 dedication of a small firm. A reputation built on trust.
Experience. Dedication. Trust. The Oliver Law Group P.C.

If you would like to learn more about filing a Xarelto lawsuit, turn to the law firm with the Experience, Dedication, and Trust you deserve. Contact The Oliver Law Group P.C. for your free Xarelto case review by calling toll free 800-939-7878 today.

Alyson Oliver, The Oliver Law Group, http://www.legalactionnow.com, +1 800-939-7878, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.